Barinthus Biotherapeutics (BRNS) Competitors $0.68 -0.02 (-2.60%) Closing price 04/15/2025 03:59 PM EasternExtended Trading$0.69 +0.01 (+1.32%) As of 09:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BRNS vs. ACTU, IKT, TNXP, PRQR, GLSI, NMRA, LRMR, FDMT, OGI, and KODShould you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Actuate Therapeutics (ACTU), Inhibikase Therapeutics (IKT), Tonix Pharmaceuticals (TNXP), ProQR Therapeutics (PRQR), Greenwich LifeSciences (GLSI), Neumora Therapeutics (NMRA), Larimar Therapeutics (LRMR), 4D Molecular Therapeutics (FDMT), Organigram (OGI), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry. Barinthus Biotherapeutics vs. Actuate Therapeutics Inhibikase Therapeutics Tonix Pharmaceuticals ProQR Therapeutics Greenwich LifeSciences Neumora Therapeutics Larimar Therapeutics 4D Molecular Therapeutics Organigram Kodiak Sciences Actuate Therapeutics (NASDAQ:ACTU) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends. Do analysts recommend ACTU or BRNS? Actuate Therapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 151.57%. Barinthus Biotherapeutics has a consensus price target of $5.17, suggesting a potential upside of 658.69%. Given Barinthus Biotherapeutics' higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ACTU or BRNS? Barinthus Biotherapeutics received 16 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformActuate TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesBarinthus BiotherapeuticsOutperform Votes17100.00% Underperform VotesNo Votes Does the media prefer ACTU or BRNS? In the previous week, Actuate Therapeutics and Actuate Therapeutics both had 2 articles in the media. Barinthus Biotherapeutics' average media sentiment score of 1.43 beat Actuate Therapeutics' score of 0.94 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Actuate Therapeutics Positive Barinthus Biotherapeutics Positive Is ACTU or BRNS more profitable? Actuate Therapeutics' return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A N/A Barinthus Biotherapeutics N/A -34.26%-29.30% Which has stronger earnings & valuation, ACTU or BRNS? Actuate Therapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$24.75MN/AN/ABarinthus Biotherapeutics$14.97M1.84-$73.35M-$1.55-0.44 Do insiders and institutionals hold more shares of ACTU or BRNS? 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 8.0% of Barinthus Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryBarinthus Biotherapeutics beats Actuate Therapeutics on 7 of the 10 factors compared between the two stocks. Remove Ads Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BRNS vs. The Competition Export to ExcelMetricBarinthus BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.47M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.466.8121.7017.82Price / Sales1.84225.96377.7294.61Price / CashN/A65.6738.1534.64Price / Book0.145.866.464.00Net Income-$73.35M$141.86M$3.20B$247.23M7 Day Performance-0.83%4.38%2.77%1.44%1 Month Performance-35.75%-12.76%-8.60%-6.26%1 Year Performance-73.08%-11.13%10.40%0.59% Barinthus Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BRNSBarinthus Biotherapeutics3.0227 of 5 stars$0.68-2.6%$5.17+658.7%-74.2%$27.47M$14.97M-0.46107Short Interest ↓Positive NewsACTUActuate TherapeuticsN/A$6.93+1.5%$20.00+188.8%N/A$135.24MN/A0.0010IKTInhibikase Therapeutics1.4363 of 5 stars$1.77+5.4%$6.50+267.0%-13.4%$131.66M$260,000.00-0.666Gap DownTNXPTonix Pharmaceuticals2.5969 of 5 stars$19.51+9.6%$585.00+2,899.1%-96.4%$128.89M$10.09M0.0050PRQRProQR Therapeutics2.169 of 5 stars$1.23+5.1%$9.50+672.4%-41.8%$128.89M$18.91M-3.83180Short Interest ↓News CoverageGLSIGreenwich LifeSciences1.9672 of 5 stars$9.71+1.2%$38.00+291.6%-37.2%$128.69MN/A-12.243Earnings ReportUpcoming EarningsNews CoverageNMRANeumora Therapeutics3.1613 of 5 stars$0.77+1.7%$9.29+1,112.2%-94.1%$125.05MN/A-0.41108Gap UpLRMRLarimar Therapeutics3.2832 of 5 stars$1.89+1.1%$19.63+938.4%-74.2%$124.21MN/A-1.6930Positive NewsFDMT4D Molecular Therapeutics2.5766 of 5 stars$2.70+1.7%$26.71+891.3%-88.2%$123.67M$37,000.00-0.94120Positive NewsGap DownOGIOrganigram0.6678 of 5 stars$0.95-0.5%N/A-44.7%$120.32M$166.12M-2.51860Positive NewsKODKodiak Sciences3.6308 of 5 stars$2.28+4.4%$9.00+295.6%-40.3%$120.21MN/A-0.6290Short Interest ↑Gap Up Remove Ads Related Companies and Tools Related Companies ACTU Competitors IKT Competitors TNXP Competitors PRQR Competitors GLSI Competitors NMRA Competitors LRMR Competitors FDMT Competitors OGI Competitors KOD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BRNS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMusk's panic move: What the world's richest man fears is comingWhether you have modest savings of $10,000 or substantial wealth of $10 million, this information could determ...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BRNS Stock Free BRNS Stock Alerts